What is Retatrutide?
Retatrutide, also known in the research literature as LY3437943, is an investigational peptide designed to activate three hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor.
Because one molecule engages all three targets, published papers commonly describe it as a triple hormone receptor agonist. That description refers to receptor pharmacology; it should not be read as an instruction for use.
Why are three receptors studied?
GIP, GLP-1 and glucagon signalling each participate in metabolic physiology. Research into retatrutide examines what happens when these pathways are activated together by a single molecule. Experimental work has looked at receptor activity, energy balance, glucose-related endpoints and other metabolic measurements.
What has research examined?
Published programmes have included receptor and animal studies as well as clinical trials. Human trials have measured endpoints including body-weight change, glycaemic measures and liver-fat-related outcomes in defined study populations. Trial results belong in the context of their protocol, population, duration and comparator.
For a research library, the useful distinction is between what a study measured and claims about what a compound should be used for. Peptrion does not provide dosing or treatment guidance.
Research status & limitations
Retatrutide is investigational. Research findings can change as larger or longer studies report. Readers should use primary papers and trial registries when evaluating a specific result and should distinguish published findings from promotional summaries.
Peptrion catalogue context
Peptrion lists a Retatrutide research material for lawful laboratory and analytical research. Product presentation, batch documentation and catalogue information are separate from clinical-trial evidence. Always review the exact product record and available batch documentation.